[{"address1": "Building 17", "address2": "Suite 102b 221 Crescent Street", "city": "Waltham", "state": "MA", "zip": "02453", "country": "United States", "phone": "650 394 5230", "website": "https://www.apogeetherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 196, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Thomas Henderson M.D.", "age": 34, "title": "CEO & Director", "yearBorn": 1990, "fiscalYear": 2024, "totalPay": 1207238, "exercisedValue": 0, "unexercisedValue": 2235652}, {"maxAge": 1, "name": "Ms. Jane Pritchett V. Henderson", "age": 58, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 879375, "exercisedValue": 0, "unexercisedValue": 983680}, {"maxAge": 1, "name": "Dr. Carl Linden Dambkowski M.D.", "age": 39, "title": "Chief Medical Officer", "yearBorn": 1985, "fiscalYear": 2024, "totalPay": 879375, "exercisedValue": 0, "unexercisedValue": 942951}, {"maxAge": 1, "name": "Ms. Noel  Kurdi", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Batters J.D.", "age": 48, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  Cox", "title": "SVP & Head of People", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rebecca  Dabora Ph.D.", "age": 65, "title": "Chief Development Officer", "yearBorn": 1959, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Wendy  Aspden-Curran", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Drew  Badger Ph.D.", "title": "Senior VP and Head of Regulatory Affairs & Toxicology", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Monica  Forbes", "age": 48, "title": "Senior Vice President of Finance", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 78.09, "open": 77.27, "dayLow": 75.84, "dayHigh": 78.33, "regularMarketPreviousClose": 78.09, "regularMarketOpen": 77.27, "regularMarketDayLow": 75.84, "regularMarketDayHigh": 78.33, "payoutRatio": 0.0, "beta": 1.422, "forwardPE": -15.56367, "volume": 548382, "regularMarketVolume": 548382, "averageVolume": 859883, "averageVolume10days": 1055820, "averageDailyVolume10Day": 1055820, "bid": 54.09, "ask": 94.87, "bidSize": 2, "askSize": 2, "marketCap": 5282520064, "fiftyTwoWeekLow": 26.2, "fiftyTwoWeekHigh": 80.99, "allTimeHigh": 80.99, "allTimeLow": 14.19, "fiftyDayAverage": 65.3711, "twoHundredDayAverage": 45.4115, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 4700754944, "profitMargins": 0.0, "floatShares": 48647548, "sharesOutstanding": 54833587, "sharesShort": 8472837, "sharesShortPriorMonth": 7931680, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.124, "heldPercentInsiders": 0.061950002, "heldPercentInstitutions": 1.12981, "shortRatio": 10.45, "shortPercentOfFloat": 0.22659999, "impliedSharesOutstanding": 68320229, "bookValue": 9.885, "priceToBook": 7.8219523, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -253674000, "trailingEps": -4.38, "forwardEps": -4.96798, "enterpriseToEbitda": -16.65, "52WeekChange": 0.7493279, "SandP52WeekChange": 0.17354333, "quoteType": "EQUITY", "currentPrice": 77.32, "targetHighPrice": 116.0, "targetLowPrice": 70.0, "targetMeanPrice": 96.84615, "targetMedianPrice": 95.0, "recommendationMean": 1.07143, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 13, "totalCash": 527288992, "totalCashPerShare": 7.813, "ebitda": -282332000, "totalDebt": 9853000, "quickRatio": 15.619, "currentRatio": 15.863, "debtToEquity": 1.68, "returnOnAssets": -0.25261, "returnOnEquity": -0.38414, "freeCashflow": -143327504, "operatingCashflow": -232475008, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "APGE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Apogee Therapeutics, Inc.", "longName": "Apogee Therapeutics, Inc.", "averageDailyVolume3Month": 859883, "fiftyTwoWeekLowChange": 51.12, "fiftyTwoWeekLowChangePercent": 1.9511449, "fiftyTwoWeekRange": "26.2 - 80.99", "fiftyTwoWeekHighChange": -3.6699982, "fiftyTwoWeekHighChangePercent": -0.045314215, "fiftyTwoWeekChangePercent": 74.93279, "earningsTimestamp": 1762781400, "earningsTimestampStart": 1762781400, "earningsTimestampEnd": 1762781400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -4.38, "epsForward": -4.96798, "epsCurrentYear": -4.18565, "priceEpsCurrentYear": -18.47264, "fiftyDayAverageChange": 11.948898, "fiftyDayAverageChangePercent": 0.18278563, "twoHundredDayAverageChange": 31.9085, "twoHundredDayAverageChangePercent": 0.70265245, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-07-14", "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1689341400000, "marketState": "CLOSED", "regularMarketPrice": 77.32, "corporateActions": [], "postMarketTime": 1766783403, "regularMarketTime": 1766782801, "exchange": "NGM", "messageBoardId": "finmb_1816591253", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -0.986037, "postMarketChangePercent": 0.0, "postMarketPrice": 77.32, "postMarketChange": 0.0, "regularMarketChange": -0.769997, "regularMarketDayRange": "75.84 - 78.33", "fullExchangeName": "NasdaqGM", "displayName": "Apogee Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-12-27"}]